Dosing and uses of Selenomax, Selepen (selenium)
Adult dosage forms and strengths
tablet
- 50mcg
- 100mcg
- 125mcg
- 200mcg
tablet extended release
- 200mcg
capsule
- 200mcg
injectable solution
- 40mcg/mL
RDa
Male or female: 55 mcg/day
Pregnancy: 60 mcg/day
Lactating: 70 mcg/day
Supplementation
100-200 mcg/day PO with meals (preferably); may take 50 mcg PO qDay or q6hr
Pediatric dosage forms and strengths
tablet
- 50mcg
- 100mcg
- 125mcg
- 200mcg
tablet extended release
- 200mcg
capsule
- 200mcg
injectable solution
- 40mcg/mL
RDa
<6 months: 15 mcg/day
6-12 months: 20 mcg/day
1-3 years: 20 mcg/day
4-8 years: 30 mcg/day
8-13 years: 40 mcg/day
13-18 years: 55 mcg/day
Selenomax, Selepen (selenium) adverse (side) effects
Frequency not defined
Irritability
Warnings
Contraindications
Undiluted injection into peripheral vein
Pregnancy and lactation
Pregnancy category: C
Lactation: Excreted in breast milk; use caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Selenomax, Selepen (selenium)
Mechanism of action
Antioxidant; cofactor in glutathione peroxidase; protects cell components from oxidative damage
Present in selenoproteins as selenocysteine amino acid residue
Pharmacokinetics
Excretion: Urine, feces, lungs, skin
